Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients

NCT03237728 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Sepsis

Interventions

DRUG: 0.06mg/kg,KB
DRUG: 0.12mg/kg,KB
DRUG: 0.24mg/,KB
DRUG: Placebos

Sponsor

Tianjin Chasesun Pharmaceutical Co., LTD

Collaborators

[object Object]